- AdventHealth Research Institute
AdventHealth Research Institute (AHRI) is proud to be the highest enrolling site in the United States for the STAR trial—a groundbreaking study testing a potential new treatment for babies with hypoxic-ischemic encephalopathy (HIE), a serious condition caused by lack of oxygen at birth.
Doubling Expectations
Thanks to the leadership of Dr. Leslie Pineda, who became a research investigator with AHRI just last year, our team has already doubled the sponsor’s enrollment goal. While the sponsor hoped for 4 enrollments, AHRI has successfully enrolled 8 babies—more than any other site in the nation.
Around-the-Clock Commitment
Because STAR is a 24-hour trial, eligible newborns can be admitted at any time, day or night. Dr. Pineda and her team have adjusted schedules and extended support across campuses to ensure every qualifying baby can be a part of this research.
To learn more about this study please click below.
Recent News
Clinical Trial Evidence on Diet and Type 1 Diabetes Outcomes
A new systematic review of clinical trials has found that no single dietary pattern consistently improves blood sugar control or weight management in youth and adults living with type 1 diabetes.
How Diet Shapes Gut Microbes and Energy Absorption
What we eat has a big impact on the bacteria living in our gut, which in turn affects how our bodies use energy—something that plays a major role in the development and treatment of obesity.
AdventHealth Neuroscience Institute Launches NIH-Funded THRIVE Trial
AdventHealth Neuroscience Institute has launched THRIVE, an NIH-funded clinical trial led by Lauren Oberlin, PhD, geriatric neuropsychologist and neuroscience researcher.
AdventHealth Tampa Enrolls First Patient in the Tectonic CAD IVL Trial
On September 19, 2025, AdventHealth Tampa successfully enrolled its first patient in the Tectonic CAD Intravascular Lithotripsy (IVL) Trial, led by Dr. Mahmaljy and his team.
MANIFEST US Study Presented as a Late-Breaking Clinical Trial at AHA
The cardiovascular team is excited to highlight the MANIFEST US study, which was presented on November 10th as a Late-Breaking Clinical Trial at the American Heart Association (AHA) Scientific...
Nourishing Your Gut: Dr. Karen Corbin on the Power of Fiber
Dr. Karen Corbin, associate investigator at the AdventHealth Translational Research Institute for Metabolism and Diabetes in Orlando, emphasizes the essential role of diet in maintaining a healthy gut...
Southeast Region – Redmond Campus: AdventHealth Recognized as Top Enroller Nationally for the CARVTOP-ICD Trial
AdventHealth Research Institute (AHRI) is proud to announce that the Southeast Region’s Redmond Campus has been recognized as the top enrolling site nationally for the CARVTOP-ICD trial.
Stiff Arteries Linked to Early Memory Decline: New Findings by Dr. Amani Norling
Amani Norling, PhD a post-doctoral fellow at the AdventHealth Neuroscience institute, has published a notable paper titled “Arterial stiffness moderates the link between NfL and cognition: The IGNITE...
First BrioVAD Implant Successfully Completed
On September 24, the Transplant team successfully implanted the first BrioVAD device at AdventHealth, a major milestone in the ongoing INNOVATE 2254936 Vidic trial.
Advancing T1D Science: New TRI Publications
Researchers at the AdventHealth Translational Research Institute continue to drive meaningful progress in Type 1 diabetes—work that is being recognized not just in Central Florida, but throughout the...
The T1D Daily Reset: Small Habits With Big Impact
As we head into 2026, many people living with Type 1 diabetes are looking for ways to reset their routines and start the year feeling more balanced and in control.
The Next Frontier: Preventing Type 1 Diabetes Before It Starts
Recent research led by AdventHealth’s Translational Research Institute and others reveals that Type 1 diabetes develops gradually and can now be detected early through blood tests, opening the door to...